Description
The Department of Veterans Affairs is issuing a sole‑source, firm‑fixed‑price order to Novartis Pharmaceuticals Corporation for 18 units of Pluvicto and 4 units of Lutathera, radiopharmaceutical therapies required by the VA Western New York Healthcare System’s Nuclear Medicine service. The procurement is justified under GSAM/R regulations because Novartis is the only authorized manufacturer/distributor of these FDA‑approved products, and no alternate sources exist. The requirement is urgent, and the VA will award the order without competition if no response is received by the deadline.
• Products: Pluvicto (18 units) and Lutathera (4 units) – Lu‑177 radioligand therapies for advanced cancers.
• Vendor: Novartis Pharmaceuticals Corp (sole authorized supplier).
• Delivery: To VA Buffalo Medical Center, Nuclear Medicine, 3495 Bailey Ave, Buffalo, NY 14215.
• Deadline for capability statements/responses: 4 pm ET, 15 Oct 2026.
• Procurement type: Sole‑source, Federal Supply Schedule (FSS) contract; no price disclosed but firm‑fixed.